by Raynovich Rod | Mar 18, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer...
by Raynovich Rod | Feb 27, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Clinical Diagnostics and Tools
Rayno Life Science Movers -Diagnostics Review Next Week Despite some choppiness in biotech trading this week many of our stocks did well. I won’t go into some of the unusual volatility in other small and mid-caps lately but that is part of the reason for my...
by Raynovich Rod | Feb 3, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
But Momentum Is Easing As Investors Cash Out-IBB Is 5.5% Off Jan 22 Highs Caution Rules With Selling Pressure-Raise Cash to 15% January 2014 was up 12% which may be the best month ever in biotechnology at peak prices on January 22. But with the sector up over 62%...
by Raynovich Rod | Jan 30, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Update 12:40p NASDAQ Up 2% Cardiovascular Sciences (CSII $33.90) Up 15 %-Beats on Revenues and EPS. Q2 Revenues up 28% to $32.3M. Net Loss was $8.7M compared to $5.8M in 2013 fiscal Q2. Thermo Fisher (TMO $114) up 2.4% on 10% 2013 EPS gain. Q4 revenues up 6% to...
by Raynovich Rod | Jan 21, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Moving Again-XBI up 1.54% After a 15%+ move January YTD you would think it is time to step back and take some off. Today the rally was in a full bull MOde with biopharmaceutical stocks leading the way. Here are big upside movers among our focus...
by Raynovich Rod | Jan 16, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech Rally Continues With IBB ($245) At New Highs-Up 10 Pts. From Monday’s Bottom Several Rayno Life Science picks were up after presentations at the 2014 J.P.Morgan Healthcare Conference. All of our portfolio picks are strong holds unless otherwise noted....
by Raynovich Rod | Jan 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market Enters The Bubblet Phase in Early 2014 (Published in Seeking Alpha on January 9) Buyers Anticipating J.P. Morgan Conference: IBB up 3.79% YTD Last week we started a series of articles that will follow key technical and fundamental trends in the...
by Raynovich Rod | Sep 3, 2013 | Biopharmaceuticals
(Published this am in Seeking Alpha) Onyx Pharmaceuticals (ONXX) $10.4B Buy-Out Fuels Speculative Deal Lists We have written extensively on the life science bull market and its underpinnings: cheap money, scientific breakthroughs, sales growth and of course, M&A....
by Raynovich Rod | Aug 26, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Life science stocks resumed their upward trajectory today with major ETFs (FBT,IBB,XBI) up over 2% and a green screen for the sector. Mid-cap biopharma stocks are strong once again. The IBB hit an August low of $187 on August 19 after a high in early August near $201....
by Raynovich Rod | Jul 25, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Diagnostics and Tools Stocks Are At New Highs We will be attending the American Association of Clinical Chemistry Meeting in Houston next week. Our focus stocks are summarized below and as you can see they have already made huge moves this year.In the past we have...
